Drug
Engasertib
Engasertib: highest development phase Phase 3, developed by Vaderis Therapeutics AG. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Vaderis Therapeutics AG
Trials
| Drug | Phase | Indication |
|---|---|---|
| Engasertib NCT07743671 | Phase 3 | Hereditary Hemorrhagic Telangiectasia |
Latest
No recent events.
Follow Engasertib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.